BiomX Inc.
Index- P/E- EPS (ttm)-1.39 Insider Own20.07% Shs Outstand28.67M Perf Week-0.01%
Market Cap25.40M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float24.04M Perf Month-50.31%
Income-36.20M PEG- EPS next Q- Inst Own22.80% Short Float0.09% Perf Quarter-53.80%
Sales- P/S- EPS this Y-6.80% Inst Trans3.02% Short Ratio1.21 Perf Half Y-60.10%
Book/sh1.66 P/B0.48 EPS next Y- ROA-48.40% Target Price8.50 Perf Year-87.03%
Cash/sh1.93 P/C0.41 EPS next 5Y- ROE-68.60% 52W Range0.64 - 6.73 Perf YTD-50.62%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-88.26% Beta-
Dividend %- Quick Ratio6.00 Sales past 5Y- Gross Margin- 52W Low23.44% ATR0.11
Employees103 Current Ratio6.00 Sales Q/Q- Oper. Margin- RSI (14)22.56 Volatility13.30% 9.74%
OptionableNo Debt/Eq0.30 EPS Q/Q7.40% Profit Margin- Rel Volume2.46 Prev Close0.81
ShortableYes LT Debt/Eq0.30 EarningsMay 11 BMO Payout- Avg Volume18.38K Price0.79
Recom- SMA20-32.97% SMA50-43.91% SMA200-62.52% Volume45,168 Change-2.47%
Apr-15-21Initiated Ladenburg Thalmann Buy $25
May-20-22 08:00AM  
May-11-22 06:30AM  
May-06-22 07:00AM  
May-05-22 08:00AM  
Mar-30-22 06:30AM  
Mar-23-22 08:00AM  
Feb-24-22 08:00AM  
Jan-04-22 07:00AM  
Nov-17-21 08:00AM  
Nov-15-21 06:00AM  
Nov-09-21 08:00AM  
Oct-25-21 10:00AM  
Oct-18-21 07:00AM  
Oct-13-21 07:00AM  
Sep-02-21 04:05PM  
Aug-16-21 06:30AM  
Aug-12-21 08:00AM  
Jul-26-21 08:13AM  
Jun-14-21 06:30AM  
Jun-09-21 06:30AM  
May-25-21 10:46AM  
May-24-21 06:30AM  
May-18-21 08:00AM  
Apr-20-21 07:00AM  
Mar-31-21 06:30AM  
Mar-24-21 06:30AM  
Mar-02-21 07:00AM  
Mar-01-21 07:00AM  
Feb-02-21 06:30AM  
Jan-04-21 06:30AM  
Dec-09-20 04:30PM  
Dec-02-20 06:21PM  
Nov-16-20 06:30AM  
Nov-12-20 06:30AM  
Nov-10-20 04:30PM  
Nov-05-20 06:30AM  
Nov-04-20 06:30AM  
Oct-21-20 06:30AM  
Oct-05-20 06:30AM  
Sep-10-20 04:30PM  
Sep-02-20 06:30AM  
Aug-13-20 06:30AM  
Aug-12-20 12:17PM  
Aug-06-20 07:00AM  
May-14-20 06:30AM  
May-11-20 05:00PM  
Apr-07-20 04:05PM  
Mar-31-20 06:30AM  
Mar-26-20 06:30AM  
Mar-20-20 08:00AM  
Feb-17-20 07:00AM  
Dec-02-19 07:30AM  
Nov-12-19 07:30AM  
Nov-04-19 05:38PM  
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). The company's lead product candidate BX001, which is in Phase II that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type. Its products under development include BX003 to treat acne-prone skin, IBD, and PSC; BX004, a therapeutic phage product candidate for chronic respiratory infections caused by pseudomonas aeruginosa; and BX005, a topical phage product candidate for staphylococcus aureus, a bacterium associated with the development and exacerbation of inflammation in atopic dermatitis, as well as CRC program targets strains of bacteria found in CRC tumors. The company has license agreement with Keio University and JSR Corporation to bacterial targets that are related to IBD and the phage to eradicate these bacterial targets. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wolfson MarinaSVP of Finance & OperationsJul 28Buy4.003,75015,0003,750Jul 30 09:55 AM
Sullivan Lynne MarieDirectorJul 28Buy4.0012,50050,00012,500Jul 30 09:53 AM
Solomon Jonathan EitanChief Executive OfficerJul 28Buy4.0025,000100,00025,000Jul 30 09:52 AM
Greig RussellDirectorJul 28Buy4.003,75015,0003,750Jul 30 09:50 AM
SEKHRI PAUL JDirectorJul 28Buy4.0012,50050,00012,500Jul 30 09:49 AM
Moses Alan CharlesDirectorJul 28Buy4.005,00020,0005,000Jul 30 09:48 AM